{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:03:48Z","timestamp":1763535828502,"version":"3.40.5"},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The aim of this study was to discuss the safety and efficacy of administering reduced doses (3 mg) of pegylated recombinant human granulocyte\u2010colony stimulating factor (PEG\u2010rhG\u2010CSF) at approximately 24\u2009h or up to three days following treatment with etoposide and cisplatin (EP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 104\u2009cycles from 31 patients were divided into a PEG\u2010rhG\u2010CSF prophylaxis group (PP\u2010Group) and a control group (No\u2010PP\u2010Group). The PP\u2010Group received a reduced dose of 3 mg of PEG\u2010rhG\u2010CSF within a minimum of 15\u2009h and a maximum of 72\u2009h following EP chemotherapy, while the rest did not receive any G\u2010CSF prophylaxis (No\u2010PP\u2010Group). For both groups, complete blood counts, incidence of febrile neutropenia (FN), grade III or IV neutropenia, and the use of antibiotics to treat neutropenia were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was statistically no significant difference in the incidence of FN (0% vs. 1.4%, <jats:italic>p<\/jats:italic> = 1), antibiotic use due to neutropenia (0% vs. 2.7%, <jats:italic>p<\/jats:italic> = 0.881), estimated lowest mean marginal (EM) platelet (106.56\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L vs. 127.70\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L, <jats:italic>p<\/jats:italic> = 0.056) and hemoglobin (110.48\u2009g\/L vs. 110.14\u2009g\/L, <jats:italic>p<\/jats:italic> = 0.906) levels between the two groups. However, when compared with the No\u2010PP\u2010group, the white blood cell count in the PP\u2010group was significantly higher (EM means: 4.95\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L vs. 2.80\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), while the incidence of grade III or IV neutropenia was significantly lower (9.1% vs. 68.1%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The administration of a low dose (3 mg) of PEG\u2010rhG\u2010CSF within approximately 24\u2009h or up to three days following EP treatment is safe and effective at reducing the risk of neutropenia. These findings bring a more flexible administration interval between PEG\u2010rhG\u2010CSF and EP treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.13883","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T08:22:56Z","timestamp":1613550176000},"page":"1154-1161","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte\u2010colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study"],"prefix":"10.1111","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7370-9094","authenticated-orcid":false,"given":"Chang","family":"Liu","sequence":"first","affiliation":[{"name":"Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Hao","sequence":"additional","affiliation":[{"name":"Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University General Hospital  Tianjin China"},{"name":"Tianjin Chest Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanlu","family":"Meng","sequence":"additional","affiliation":[{"name":"Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuyu","family":"Wen","sequence":"additional","affiliation":[{"name":"Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6483-8134","authenticated-orcid":false,"given":"Diansheng","family":"Zhong","sequence":"additional","affiliation":[{"name":"Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3421-x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1495621"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2015.12.002"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3842-1"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.72"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3703-y"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-3036-7"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.091094"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.11.1690"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00578558"},{"key":"e_1_2_7_12_1","unstructured":"National Comprehensive Cancer Network.Hematopoietic growth factors. Version 2.2020. [cited 2020 Aug 6]. Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1519504"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3607-7"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyw152"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw325"},{"key":"e_1_2_7_17_1","first-page":"868","article-title":"Guidelines for standardized management of neutropenia induced by chemotherapy and radiotherapy","volume":"39","author":"Chinese Society of Clinical Oncology Guidance Working Committee","year":"2017","journal-title":"Zhong hua Zhong Liu Za Zhi."},{"key":"e_1_2_7_18_1","first-page":"461","article-title":"Expert consensus on the clinical application of mecapegfilgrastim","volume":"5","author":"Chinese Society of Clinical Oncology (CSCO) Anti Tumor Drugs Safety Management Committee","year":"2020","journal-title":"Lin Chuang Zhong Liu Xue Za Zhi."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1979253351"},{"key":"e_1_2_7_20_1","first-page":"1310","article-title":"Clinical and pharmacological studies with cis\u2010diamminedichloroplatinum (II)","volume":"33","author":"DeConti RC","year":"1973","journal-title":"Cancer Res."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.24"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3193-3"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.12.003"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2017.11.003"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000487"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4373-0"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.10.013"},{"key":"e_1_2_7_29_1","first-page":"495","article-title":"Phase I clinical trial of intravenous pegylated recombinant human granulocyte colony\u2010stimulating factor","volume":"25","author":"Shi YK","year":"2006","journal-title":"Ai Zheng."}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.13883","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.13883","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.13883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T17:11:19Z","timestamp":1693588279000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.13883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/1759-7714.13883"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.13883","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"type":"print","value":"1759-7706"},{"type":"electronic","value":"1759-7714"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"2020-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}